News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘Leukemia’ clear

  • Children with acute lymphoblastic leukemia (ALL) who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, despite having received the same treatment. The findings are significant because ALL that relapses early is more difficult to successfully treat.

Tags: ChildhoodCancer, Disparities, Leukemia

  • New treatments for leukemia, colorectal cancer, brain cancer, lung cancer and breast cancer topped the list of most important research and clinical developments at Dana-Farber in 2015.

Tags: BreastCancer, ColonCancer, LungCancer, Leukemia, BrainTumors

  • Preclinical data from four studies presented at the annual meeting of the American Society of Hematology highlight potential treatment opportunities for acute myeloid leukemia (AML), a blood cancer accounting for approximately 20 percent of all childhood leukemias and 32 percent of adult leukemias. The research focuses on multiple vulnerabilities, including aspects of the cells' metabolism, internal communications and ability to transport proteins.

Tags: Leukemia

  • Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center. While the overall cure rate for ALL is high, about one to two percent of children die during the first month of therapy from treatment complications, primarily infection-related.

Tags: ChildhoodCancer, Leukemia

  • Dana-Farber scientists report that midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia.

Tags: TargetedTherapy, Leukemia

  • Dana-Farber researchers report using a pediatric chemotherapy regimen to treat young adults ages 18-50 with acute lymphoblastic leukemia significantly improved their outcomes compared to what has historically been achieved with "adult" treatment protocols.

Tags: Leukemia

  • A new study charts the "genomic biography" of chronic lymphocytic leukemia, identifying gene mutations driving its growth, and tracing the shift in mutations as the disease progresses and develops resistance to chemotherapy, demonstrating the power of sequencing DNA in a large group of tumor tissue samples.

Tags: Genomics, Leukemia

  • Dana-Farber's David Weinstock, MD, and colleagues report that a novel compound stops B-cell acute lymphoblastic leukemia tumor cell growth in pre-clinical studies; approach may be effective in other cancers as well.

Tags: BasicResearch, Leukemia

  • Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to research presented at the annual American Society of Hematology annual meeting in San Francisco.

Tags: ChildhoodCancer, Survivorship, Leukemia

  • A study led by Dana-Farber investigators found that a phase 1 trial of an immune checkpoint blocker found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation.

Tags: MultipleMyeloma, Leukemia, Immunotherapy

Showing 1-10 of 37 items